Inside Drug Pricing

AARP: Prices Of Top Drugs Not Picked For Negotiation Skyrocket

By Gabrielle Wanneh / January 10, 2025 at 5:20 PM

List prices for the top 25 most expensive Medicare Part D drugs not selected for Medicare price negotiation have risen by an average of 98% since the drugs first entered the market, a new analysis of 2022 Part D spending data released Thursday (Jan. 9) by the AARP Public Policy Institute found.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

AARP: Prices Of Top Drugs Not Picked For Negotiation Skyrocket

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.